Manthan D Janodia

Informed consent: Issues and challenges.

Informed consent is an ethical and legal requirement for research involving human participants. It is the process where a participant is informed about all aspects of the trial, which are important for the participant to make a decision and after studying all aspects of the trial the participant voluntarily confirms his or her willingness to participate in a particular clinical trial and significance of the research for advancement of medical knowledge and social welfare. The concept of informed consent is embedded in the principles of Nuremberg Code, The Declaration of Helsinki and The Belmont Report. Informed consent is an inevitable requirement prior to every research involving human being as subjects for study. Obtaining consent involves informing the subject about his or her rights, the purpose of the study, procedures to be undertaken, potential risks and benefits of participation, expected duration of study, extent of confidentiality of personal identification and demographic data, so that the participation of subjects in the study is entirely voluntary. This article provides an overview of issues in informed consent: The obligations of investigator, sponsor and Institutional Review Board to protect rights and welfare of human research subjects. It discusses about the basic elements of informed consent and the process to be followed while obtaining informed consent. Some of the circumstances under which informed consent can be waived and ethical challenges faced by physicians in obtaining informed consent from subjects are also highlighted in this article.

Medical device vigilance systems: India, US, UK, and Australia

The term medical device includes a wide category of products ranging from therapeutic medical devices exerting their effects locally such as tissue cutting, wound covering or propping open clogged arteries, to highly sophisticated computerized medical equipment and diagnostic medical devices. To achieve uniformity among the national medical device regulatory systems and increase the access to safe, effective, and clinically beneficial medical technologies, the Global Harmonization Task Force (GHTF) was conceived in 1992 by five members: European Union, United States, Australia, Japan, and Canada. All regulated countries have clearly defined medical devices, as has the GHTF. Although GHTF has tried to achieve harmonization with respect to medical devices, some differences still exist in the national laws of the countries of GHTF. Further, regulated countries have classified medical devices on the basis of their associated risk. In the Indian regulatory system, medical devices are still considered as drugs. In 2006, the Medical Device Regulation Bill was recommended to consolidate laws for medical devices and to establish the Medical Device Regulatory Authority of India. In addition, medical devices are not classified by any Indian regulatory authority. Although India has moved towards harmonizing its medical device regulations with those of regulated countries, this study aims to identify whether India should have a vigilance system in harmony with those of GHTF or develop its own system for medical devices.

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern

al a and an a a n o A o and aii i an o i l 3 i la an indi no om an lon i a ma a o a o o li o o om ani in ndia in a in n o o i n om ani amon o a ma i al om ani in ndia i ma d o a o i a n d in n a aii i an o a l adin a an a ma i al om an i i a all a oin oldin om an o an o o d and aii i o d ad a i d a ma o i a in an a a o a o i n n m on a ma i al om an in ndia n l in o i a a a d lo al ial a ma i al and m di a ion d li om an a i d id mi al in a l in o million A o a a d om an a i d i amal al a dom i o m la ion in o 3 illion and i B n i a a d om an o a a a ma o million i aid a i a o on in oon o i n a ma i al om ani on ol n a l o ndian d ail ma im a o a o o ld an in om in d i o ma ma o i n om ani o on n i a om ani i a n o o i n om ani a ma o od o a n i ion o n ial m di in and a in i n i ma a in ndia and o d lo in o n i

Development of a sustainable access to medicine model in the Caribbean: a case study of the chronic disease assistance program

Background The Caribbean region is one where there is a marked increase in non-communicable diseases and at the same time there are significant financial constraints. This study seeks to develop a methodology for a sustainable supply chain mechanism for medicines which can be implemented in these countries. To develop this, the chronic disease assistance programme currently implemented in Trinidad and Tobago was assessed and a template was developed around this.